William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota, USA.
William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota, USA.
Kidney Int. 2017 May;91(5):1193-1202. doi: 10.1016/j.kint.2016.12.016. Epub 2017 Feb 21.
Kidney allografts transplanted simultaneously with liver allografts from the same donor are known to be immunologically privileged. This is especially evident in recipients with high levels of donor-specific anti-HLA antibodies. Here we investigated the mechanisms of liver's protective impact using gene expression in the kidney allograft. Select solitary kidney transplant or simultaneous liver-kidney transplant recipients were retrospectively reviewed and separated into four groups: 16 cross-match negative kidney transplants, 15 cross-match positive kidney transplants, 12 cross-match negative simultaneous liver-kidney transplants, and nine cross-match-positive simultaneous liver-kidney transplants. Surveillance biopsies of cross-match-positive kidney transplants had increased expression of genes associated with donor-specific antigens, inflammation, and endothelial cell activation compared to cross-match-negative kidney transplants. These changes were not found in cross-match-positive simultaneous liver-kidney transplant biopsies when compared to cross-match-negative simultaneous liver-kidney transplants. In addition, simultaneously transplanting a liver markedly increased renal expression of genes associated with tissue integrity/metabolism, regardless of the cross-match status. While the expression of inflammatory gene sets in cross-match-positive simultaneous liver-kidney transplants was not completely reduced to the level of cross-match-negative kidney transplants, the downstream effects of donor-specific anti-HLA antibodies were blocked. Thus, simultaneous liver-kidney transplants can have a profound impact on the kidney allograft, not only by decreasing inflammation and avoiding endothelial cell activation in cross-match-positive recipients, but also by increasing processes associated with tissue integrity/metabolism by unknown mechanisms.
同种异体肾移植和肝移植同时移植的肾移植受者被认为具有免疫特权。这在具有高水平供体特异性抗 HLA 抗体的受者中尤为明显。在这里,我们使用肾移植中的基因表达来研究肝的保护作用的机制。回顾性分析了选择的单纯肾移植或同时肝-肾移植受者,并将其分为四组:16 例交叉配型阴性肾移植、15 例交叉配型阳性肾移植、12 例交叉配型阴性同时肝-肾移植和 9 例交叉配型阳性同时肝-肾移植。与交叉配型阴性肾移植相比,交叉配型阳性肾移植的监测活检显示与供体特异性抗原、炎症和内皮细胞激活相关的基因表达增加。这些变化在与交叉配型阴性同时肝-肾移植相比时,在交叉配型阳性同时肝-肾移植活检中未发现。此外,无论交叉配型状态如何,同时移植肝脏都会显著增加与组织完整性/代谢相关的基因在肾脏中的表达。虽然同时肝-肾移植中交叉配型阳性受者的炎症基因表达集的表达并未完全降低到交叉配型阴性肾移植的水平,但供体特异性抗 HLA 抗体的下游效应被阻断。因此,同时肝-肾移植对肾移植受者的影响非常深远,不仅可以通过减少炎症和避免交叉配型阳性受者的内皮细胞激活,还可以通过未知机制增加与组织完整性/代谢相关的过程。